Allogene Therapeutics posted early Phase 3 Alpha3 data suggesting its off-the-shelf CAR-T cemacabtagene ansegedleucel (cema-cel) can drive minimal residual disease (MRD) negativity in first-line consolidation large B-cell lymphoma. In the company’s interim futility analysis, 7 of 12 patients achieved MRD negativity at day 45 versus 2 of 12 in an observation arm. Allogene said the absolute difference cleared thresholds cited in the peer-reviewed literature as potentially important for delaying relapse, while also reporting a safety profile without severe immune or neurological toxicity signals at this interim stage. The company is enrolling 220 patients and expects to report full results in 2027 to determine whether the MRD signal translates into longer-term relapse outcomes. The data further define the strategy Allogene has pursued since spinning out of Pfizer’s cell-therapy work: testing donor-derived CAR-T earlier in disease courses where manufacturing convenience could widen access.